New York, January 13, 2026, 14:47 ET — During regular trading hours
- Alnylam shares slipped roughly 0.1% in afternoon trade as investors digested new targets alongside initial sales data
- Company projects combined net product revenue between $4.9 billion and $5.3 billion for 2026
- Analysts stayed mostly bullish but warned that Amvuttra’s upcoming quarter might underperform
Shares of Alnylam Pharmaceuticals slipped 0.1% to $370.39 in Tuesday afternoon trading, as investors weighed the company’s updated sales forecast alongside its new five-year strategy.
Based in Cambridge, Massachusetts, the company revealed preliminary 2025 sales and 2026 guidance in a Form 8-K tied to its “Alnylam 2030” plan. It warned that these figures are unaudited and may be revised before the full results come out in February. (Streetinsider)
The news came through as executives and investors gathered at the annual J.P. Morgan Healthcare Conference, a key week when biotech firms frequently revise their outlooks. Alnylam’s fate now depends on Amvuttra and its pace of growth in ATTR cardiomyopathy, a heart condition driven by buildup of a misfolded protein known as transthyretin, or TTR.
Alnylam disclosed in an 8-K exhibit that it expects preliminary net product revenue for 2025 to hit $2.987 billion. For 2026, the company projects combined net product revenue between $4.9 billion and $5.3 billion, with $4.4 billion to $4.7 billion coming from its TTR drugs Amvuttra and Onpattro. “Our focus for the next five-year period is clear: continue to establish durable leadership in TTR,” CEO Yvonne Greenstreet said. (Fast Edgar Archive)
Alnylam’s long-term goals outpace its recent quarterly results. The company aims to top the TTR market in revenue by 2030 and targets a compound annual growth rate exceeding 25% through that year. It also expects to maintain a non-GAAP operating margin of about 30%, a profitability measure that strips out one-off expenses. (Nasdaq)
Wall Street’s initial reaction leaned positive despite some grumbles about the quarter. H.C. Wainwright stuck with a buy rating, highlighting “continued momentum, particularly in the TTR franchise,” which it said “could surprise to the upside,” according to a note referenced by Investing.com. The same source reported that Needham bumped its price target to $529, while Goldman Sachs held firm on a buy rating with a $580 target. (Investing.com)
Alnylam’s management emphasized their extended timeline at JPMorgan. “The company shared numerous updates yesterday,” JPMorgan analyst Jessica Fye noted at the session’s start, according to a transcript. Greenstreet highlighted to attendees that the firm’s blend of commercial scale and research “has fueled our success to date.” (Seeking Alpha)
Competition in ATTR is heating up as drugmakers target an expanding base of heart patients, making quarterly sales a key indicator of market share. Pfizer markets tafamidis for ATTR cardiomyopathy, while newer players like BridgeBio are making inroads. Alnylam’s main technology is RNA interference, or RNAi, which shuts down the genetic signals that produce harmful proteins.
The upside scenario hinges on several factors. The 2025 numbers remain preliminary, while the 2026 forecast depends largely on Amvuttra maintaining its strong position in cardiomyopathy. Any delays in uptake, pricing challenges, or reimbursement hurdles might derail that growth path. Pipeline ambitions introduce extra uncertainty, as clinical timelines and data releases often face delays.
Alnylam’s full Q4 results and 2025 earnings report in February stand as the next major test for investors. The company has indicated it will offer updated guidance on collaboration and royalty income, as well as operating costs, giving a clearer picture of 2026’s outlook.
